INTRODUCTION {#S1}
============

Mammalian B lymphocyte development is a tightly regulated multi-step process that proceeds from hematopoietic stem cells (HSCs) in the bone marrow through several intermediate progenitor cell stages, including multipotent progenitors (MPPs), earliest lymphocyte progenitors (ELPs), and common lymphoid progenitors (CLPs), before differentiation into B cells. Intensive studies over the past decades have implicated multiple key transcription factors (TFs) in the regulation of B cell development, including factors (e.g., PU.1, Ikaros, BCL11a, E2A, EBF, and -PAX5) that act either positively to promote B cell-specific gene expression or negatively to repress non-B lineage programs ([@R3]; [@R30]). These sequence-specific TFs achieve activation or repression of target genes through interactions both with the general transcription machinery and with chromatin regulators (e.g., histone modification enzymes and chromatin remodeling complexes), but how specific chromatin regulators contribute to B cell development remains largely unknown ([@R4]).

Among chromatin-modifying factors, the heterogeneous NuRD (nucleosome remodeling histone deacetylase) complex is of special interest because it possesses both ATP-dependent nucleosome remodeling and histone deacetylase activities. The mammalian NuRD complexes are composed of both common factors (HDAC1/2, RbAp46/48) and variable modular factors that result in related heterogeneous complexes that likely modulate different transcriptional programs ([@R5]; [@R7]). Thus, beyond the common components, NuRD complexes variably contain a member (either CHD3/MI-2α or CHD4/MI-2β) of the CHD family of ATP-dependent chromatin remodeling factors, a member (MTA1, MTA2, or MTA3) of the metastasis-associated factor MTA family, a member (MBD2 or MBD3) of the methyl-CpG binding domain proteins, and either P66α or P66β (whose functions are likely to be mediated through interactions with core histones and MBD2) ([@R5]; [@R6]). *In vivo* and cell-based studies have demonstrated important and non-redundant functions of different NuRD modular components in multiple biological processes that include embryonic stem cell (ESC) maintenance, tumor progression, circadian clock regulation, synaptic differentiation, and granule neuron function in the cerebellum cortex ([@R5]; [@R6]; [@R19]; [@R38]; [@R48]; [@R49]).

In relation to NuRD function in lymphogenesis, of primary interest here, previous studies have demonstrated (1) an association of MI-2β/NuRD with IKAROS and AIOLOS in T cells ([@R1]; [@R52]); (2) reductions in CD4^+^ T cell number and *Cd4* gene expression ([@R47]); (3) abnormal HSC homeostasis and defective differentiation into myeloid and lymphoid lineages ([@R50]), following *Mi-2*β inactivation; (4) an MI-2β requirement for maintaining DNA-hypermethylated chromatin at the *mb1* gene promoter ([@R10]); (5) spontaneous B cell lymphomagenesis following *Mta1* overexpression *in vivo* ([@R2]); (6) an important role for *Mta3* in plasma cell differentiation ([@R9]); and (7) MBD3/NuRD-mediated repression of the B cell transcription program in multipotent lymphoid progenitors in order to maintain a balanced differentiation of T and B lineage cells ([@R26]). Related, our previous data showed that *Mta2*-deficient mice develop lupus-like autoimmune symptoms ([@R27]). However, the role of distinct NuRD complexes in normal B cell development and the transcriptional programs they regulate remain to be elucidated.

Here, we have characterized a number of conventional, conditional mutant and double-mutant mouse models in order to delineate specific phenotypes in B cell development, allowing us to link the MTA2 component of the MTA2/NuRD complex to the lymphocyte-specific transcription factor AIOLOS and the B cell-specific transcription coactivator OCA-B ([@R28]; [@R43]) *in vivo*. We also identified distinct groups of genes regulated by MTA2 in pro-B and pre-B cells.

RESULTS {#S2}
=======

B Cell Developmental Defects in *Mta2* Conventional and Conditional Knockout (KO) Mice {#S3}
--------------------------------------------------------------------------------------

To understand the function of MTA2/NuRD in B cell development, we first analyzed the bone marrow (BM) B cell subpopulations in 1.5- to 2.5-month-old *Mta2* conventional null (Δ/Δ) (n = 5) and littermate control mice that include both wild type and *Mta2* heterozygous mice (n = 11). The *Mta2* null strain was derived by crossing *EIIa-Cre* transgenic mice with *Mta2*^fl/fl^ mice ([@R27]). *Mta2* null mice showed decreased frequencies of immature B (B220^lo^IgM^+^), mature B (B220^hi^IgM^+^), pro-B (also called pre-BI, B220^+^IgM^−^CD43^+^), and pre-B (also called pre-BII, B220^+^IgM^−^CD43^−^) cells in BM ([Figure 1A](#F1){ref-type="fig"}). On average, the absolute numbers of total BM B (B220^+^), pro-B, pre-B, and immature B cells in *Mta2* Δ/Δ mice were about one-third to one-half of those in control mice ([Figure 1B](#F1){ref-type="fig"}). Regarding the B cell repertoire in the periphery, and while a decrease of marginal zone B (MZB) cells (IgM^+^B220^+^CD21^hi^CD23^lo^) has been observed in young *Mta2* Δ/Δ mice (6--8 weeks), this defect is more consistent and severe in mice older than 3 months old ([Figures 1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}). The number of follicular B (FOB) cells (IgM^+^B220^+^CD21^−^CD23^hi^) in adult *Mta2* Δ/Δ mice remains largely normal ([Figures 1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}).

To avoid the experimental obstacle caused by partial embryonic lethality of *Mta2* Δ/Δ mice ([@R27]) and, more importantly, to assess the B cell-autonomous defects, we generated *Cd19-Cre*- and *Mb1-Cre* (*Cd79a*) *Mta2* conditional KO mice. These *Mta2* conditional KO mice were backcrossed with C57/BL6 mice for at least six generations. *Cd19* encodes a B cell-specific cell surface signaling molecule, CD19, that is presented on all B220^+^CD43^+^HSA^+^ cells (a mixture of pro-B and large pre-B cells), but not on the earliest B220-expressing cells (B220^+^CD43^+^HAS^−^) ([@R20]). *Mb1* encodes the Igα subunit of the pre-BCR (B cell receptor) complex and is expressed earlier in development than *Cd19* ([@R12]). Surprisingly, fluorescence-activated cell sorting (FACS) analysis showed largely normal pro-B and pre-B cell compartments in *Cd19-Cre Mta2*^fl/fl^ and *Mb1-Cre Mta2*^fl/fl^ mice ([Figures S1A](#SD1){ref-type="supplementary-material"}--[S1C](#SD1){ref-type="supplementary-material"}). Subsequent qPCR data revealed that more than 85% of the pro-B cells from *Cd19-Cre Mta2*^fl/fl^ mice and 30%of the pro-B cells from *Mb1-Cre Mta2*^fl/fl^ mice still maintain the wild-type *Mta2* alleles ([Figure S1D](#SD1){ref-type="supplementary-material"}), partially explaining the lack of pro-B phenotype in these mutant mice. In contrast, both pre-B and immature B cells from *Cd19-Cre Mta2*^fl/fl^ mice, especially those B cell subsets from *Mb1-Cre Mta2*^fl/fl^ mice, show high deletion efficiencies of the *Mta2* allele ([Figure S1D](#SD1){ref-type="supplementary-material"}). Intriguingly, in relation to splenic B cell development, while *Mta2* Δ/Δ mice show loss of MZB cells, both *Cd19-Cre Mta2*^fl/fl^ and *Mb1-Cre Mta2*^fl/fl^ show increases in MZB cell numbers and MZB frequencies in total spleen cells ([Figure S2](#SD1){ref-type="supplementary-material"}). To avoid the complexity caused by escaper pro-B cells (cells maintaining the floxed *Mta2* allele) in *Cd19-Cre Mta2*^fl/fl^ and *Mb1-Cre Mta2*^fl/fl^ mice, we generated *Vav-Cre Mta2*^fl/fl^ mice in which *Cre* transgene expression begins at the HSC stage ([@R31]). FACS analyses revealed decreased population sizes of pro-B, pre-B, immature B cell, and recirculating B cell compartments in *Vav-Cre Mta2*^fl/fl^ mice, thus recapitulating the BM B cell defects of conventional null mice ([Figures 2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}) and supporting the notion that *Mta2* is required for normal development of pro-B cells. qPCR results also show optimal deletion efficiencies in different BM B cell subsets ([Figure 2C](#F2){ref-type="fig"}). Within the pro-B cell population, there is more than 50 percent reduction in both Hardy Fractions B (Fr. B) and C (Fr. C) cells when MTA2 is lost ([Figure 2D](#F2){ref-type="fig"}). qPCR analyses show that *Mta2* inactivation results in abnormal rearrangement of immunoglobulin (*Ig*) heavy chain genes (such as *V*~*H*~*J558-J*~*H3*~ and *V*~*H*~*J7183-J*~*H3*~) in pro-B cells ([Figure 2E](#F2){ref-type="fig"}). Regarding the pre-B cell population, *Vav-Cre Mta2*^fl/fl^ mice contain a higher percentage of large pre-B cells and fewer small pre-B cells than control mice ([Figure 2F](#F2){ref-type="fig"}), suggesting a cell cycle defect in these mutant pre-B cells (which might explain the decreased number of immature B cells in mutant mice). In addition, we also find abnormal Ig k chain rearrangements in *Vav-Cre Mta2*^fl/fl^ small pre-B cells ([Figure 2G](#F2){ref-type="fig"}). Furthermore, the distal recombination events seem to be more affected by *Mta2* inactivation than are the proximal recombination events, suggesting a premature termination of the recombination process ([Figure 2G](#F2){ref-type="fig"}).

MTA2/NuRD-AIOLOS/IKAROS Interaction and MTA2-Dependent Repression of Pre-BCR Genes {#S4}
----------------------------------------------------------------------------------

Altogether, the B cell phenotypes described above, as well as other defects of the immune system caused by *Mta2* inactivation ([@R27]), were reminiscent of those found in mice lacking AIOLOS, a member of the IKAROS family and a key regulator of lymphocyte function ([@R46]). IKAROS and AIOLOS were found to be stably associated with NuRD complexes in T cells ([@R16]; [@R52]). To assess whether MTA2/NuRD interacts with AIOLOS in B cells, nuclear extracts (NEs) from human pre-B leukemia 697 cells were subjected to immunoprecipitation with antibodies to MTA2, MI-2β, AIOLOS, and IKAROS ([Figure 3A](#F3){ref-type="fig"}). The results show reciprocal co-immunoprecipitation between AIOLOS, IKAROS, and NuRD components MTA2 and MI-2β ([Figure 3A](#F3){ref-type="fig"}), and were confirmed with NE from Namalwa cells (of germinal center origin) ([Figure S3A](#SD1){ref-type="supplementary-material"}). Thus, both phenotypic similarities and direct biochemical evidence suggested that *Mta2*-deficient mice may have other B cell developmental defects similar to those observed in *Aiolos* KO mice.

During mouse BM B cell development, immunoglobulin heavy chain (IgM) rearrangement occurs at the pro-B stage. The heavy chain then associates with the surrogate light chain (SLC), composed of LAMBDA5 (λ5) and VPREB proteins. *Aiolos* expression is upregulated at the pro-B to pre-B cell transition stage, and *Igll1* (encoding λ5) and *VpreB1* genes are downregulated at the pre-B stage. In *Aiolos*-null pre-B cells, both *Igll1* and *VpreB1* are derepressed---demonstrating a key role of Aiolos in silencing these genes at this stage ([@R14]; [@R44]). In addition, *Ikaros* overexpression in mouse pre-B cells also results in decreased *Igll1* expression ([@R8]). To test whether MTA2 is also involved in pre-BCR gene silencing, we examined *Igll1* and *VpreB1* expression levels in small pre-B cells (B220^+^IgM^−^CD43^−^) sorted from *Vav-Cre Mta2*^fl/fl^ and control mice ([Figure S3B](#SD1){ref-type="supplementary-material"}). The RT-qPCR results show marked increases in expression of these genes in *Mta2-*deficient pre-B cells and are confirmed in *Mx1-Cre Mta2*^fl/fl^ pre-B cells ([Figure 3B](#F3){ref-type="fig"}). The increase of *Igll1* and *VpreB1* expression is further confirmed in *Vav-Cre Mta2*^fl/fl^ pre-B cells sorted by an alternative gating scheme (B220^+^IgM^−^CD43^−^CD25^+^) ([Figures S3C](#SD1){ref-type="supplementary-material"} and [S3D](#SD1){ref-type="supplementary-material"}). To examine whether MTA2/NuRD regulates pre-BCR genes directly, chromatin immunoprecipitation (ChIP) as-says were performed using 697 human pre-B leukemia cells. The data demonstrate significant enrichments of MTA2, MI-2β, AIOLOS, and IKAROS at *IGLL1* and *VPREB1* promoters ([Figure 3C](#F3){ref-type="fig"}). Thus, both genetic and biochemical experiments clearly demonstrate that MTA2/NuRD directly interacts with AIOLOS and IKAROS in developing B cells, and jointly targets pre-BCR gene loci. ChIP assays demonstrated that loss of MTA2 activity leads to increase of histone H3 lysine 27 acetylation (H3K27Ac) at both *Igll1* and *VpreB1* promoters ([Figure 3D](#F3){ref-type="fig"}), indicating the mechanism underlying the increased *Igll1* and *VpreB1* expression in *Mta2*-deficient pre-B cells.

Highly Overlapping Genomic Distributions of MTA2, HDAC2, AIOLOS, and IKAROS in Human Pre-B Cells {#S5}
------------------------------------------------------------------------------------------------

To better understand the MTA2/NuRD-dependent gene regulation and its relationship to AIOLOS and IKAROS, we examined the genomic distributions of MTA2, HDAC2 (another subunit of NuRD complex), AIOLOS, and IKAROS in 697 cells by chromatin immunoprecipitation sequencing (ChIP-seq). These analyses identified about 28,760 MTA2 peaks, with 19% at promoter regions, 44% at intragenic regions (including introns, exons, 5^′^and 3^′^ UTR regions), and 34% at intergenic regions (including distal enhancers) ([Figure 4A](#F4){ref-type="fig"}). HDAC2, AIOLOS, and IKAROS showed similar distribution patterns ([Figure 4A](#F4){ref-type="fig"}). A further examination of the average distance from the binding sites of these factors to transcription start sites (TSSs) and enhancers revealed enrichment of all these factors slightly upstream of the TSS ([Figure 4B](#F4){ref-type="fig"}). At enhancer regions, all four factors showed almost the same binding patterns ([Figure 4B](#F4){ref-type="fig"}). Furthermore, the ChIP-seq data showed a striking overlap between target genes bound by these factors ([Figure 4C](#F4){ref-type="fig"}). For example, about 90% of the MTA2 target genes are also AIOLOS targets, more than 90% of the HDAC2 targets are also MTA2 targets, and more than 90% of AIOLOS targets are also IKAROS targets ([Figure 4C](#F4){ref-type="fig"}). A heatmap generated by normalized read densities from individual ChIP-seq data centered at TSSs and ranked by AIOLOS peak signals further demonstrates the high degree of AIOLOS/IKAROS and MTA2/HDAC2 colocalization at promoter regions ([Figure 4D](#F4){ref-type="fig"}). These data strongly support a model in which AIOLOS/IKAROS recruits the MTA2/NuRD complex to repress target genes in pre-B cells.

Toward the identification of DNA sequence elements recognized by MTA2, HDAC2, AIOLOS, and IKAROS, respectively, motif analyses indicated that the top binding sites preferred by MTA2, HDAC2, and AIOLOS/IKAROS include motifs recognized by EBF1, RUNX1, and ETS family members (FLI1, ERG, and ETV2) ([Figure 4E](#F4){ref-type="fig"}). The more detailed summaries of DNA motifs recognized by these factors are listed in [Tables S1](#SD1){ref-type="supplementary-material"}--[S4](#SD1){ref-type="supplementary-material"}. These data suggest a model in which AIOLOS/IKAROS/NuRD function, at least partially, by repressing target genes of EBF1, RUNX1, and ETS family transcription factors in pre-B cells. This notion is consistent with a previously proposed model that AIOLOS represses *Igll1* expression at the pre-B stage by competing with EBF1 at the same DNA binding site ([@R44]).

The ChIP-seq data also confirm that the *IGLL1* and *VPREB1* promoters are loaded with AIOLOS and NuRD components MTA2 and HDAC2 ([Figure 4F](#F4){ref-type="fig"}), and that this is also the case for the promoters of the *CD79A* and *CD79B* genes (encoding the Igα and Igβ subunits of the pre-BCR/BCR complexes) ([Figure 4F](#F4){ref-type="fig"}). For a group of genes, such as *CD86* and *BCL2*, AIOLOS/IKAROS and NuRD do not bind to the promoter regions but instead bind to the intronic and 3^′^ UTR elements ([Figures S4A](#SD1){ref-type="supplementary-material"} and [S4B](#SD1){ref-type="supplementary-material"}). Interestingly, the expression levels of *Cd86* and *Bcl2* are elevated in *Mta2-*deficient murine pre-B cells (data not shown), suggesting a possible enhancer-mediated transcription repression for these genes.

MTA2-Dependent Transcriptional Program in Pro-B and Pre-B Cells {#S6}
---------------------------------------------------------------

To understand the molecular basis of pro-B and pre-B defects observed in *Vav-Cre Mta2*^*fl*/fl^ mice and to assess MTA2/NuRD-regulated transcriptional programs in these cells, we performed RNA-sequencing (RNA-seq) analyses using pro-B cells and small pre-B cells from *Vav-Cre Mta2*^fl/fl^ and control mice (the cell sorting strategies are like the ones shown in [Figure S3B](#SD1){ref-type="supplementary-material"}) ([Figure 5A](#F5){ref-type="fig"}). Consistent with the observation that MTA2 enhances HDAC activity *in vitro*, as well as a general role of HDACs in gene repression ([@R7]), many more genes were upregulated (440 genes \>1.5-fold) than downregulated (88 genes \>1.5-fold) in pro-B cells upon *Mta2* inactivation ([Figure 5B](#F5){ref-type="fig"}). Among upregulated genes, about 8% (37) showed more than 3-fold increases in expression, while the rest (403) showed 1.5- to 3-fold increases in expression ([Figure 5B](#F5){ref-type="fig"}). Among downregulated genes, about 6%(5) showed more than 3-fold reductions in expression, whereas 94% (83) showed 1.5- to 3-fold reductions ([Figure 5B](#F5){ref-type="fig"}). A gene ontology (GO) analysis of upregulated genes in *Mta2*-deficient pro-B cells showed that the top enriched pathways or cellular processes include neutrophil degranulation and activation (e.g., *Cd14*, *Cd63*, *Chit1*, *Ckap4*, *Lrg1*, etc.); inflammatory responses (e.g., *Cebpb*, *Csf1r*, *Ptgir*, *Cd6*, *Cxcr2*, etc.); cell junction and extracellular matrix (ECM) relationships (e.g., *Tjp1*, *Prtn3*, *Itgb4*, *Col5a1*, etc.); macromolecule metabolism (e.g., *Acvrl1*, *ccr1*, and *Cd3e*, etc.); and endocytosis (e.g., *Cd63 Lrp1*, *Hip1*, *Apoe*, etc.) ([Figure 5C](#F5){ref-type="fig"}). Other genes that showed more substantial (\>3-fold) upregulation in Mta2-deficient pro-B cells include the following: *Gpr4*, *Asprv1*, *Rcn3*, *Ly6a*, *Padi3*, etc.

In the small pre-B cell compartment, there also were more genes upregulated (435 genes) than downregulated (229 genes) upon *Mta2* inactivation (\>1.5-fold) ([Figure 5B](#F5){ref-type="fig"}). Among upregulated genes, about 15% (62) showed more than 3-fold increases in expression, while the rest (373) showed 1.5- to 3-fold increases in expression ([Figure 5B](#F5){ref-type="fig"}). Among downregulated genes, only 5% (12) showed more than 3-fold reductions in expression, whereas 95% showed 1.5- to 3-fold reductions ([Figure 5B](#F5){ref-type="fig"}). A GO analysis showed that the top enriched pathways/cellular processes in *Mta2*-deficient pre-B cells include the following: T cell receptor (TCR) and T cell differentiation (e.g., *Lck*, *Thy1*, *Lat*, *Zap70*, etc.), regulation of apoptosis (e.g., *Bcl2*, *Ccnd2*, *Socs2*, *c-Kit*, etc.), and inositol phosphate metabolism (e.g., *Plcd3*, *Plcb3*, *Inpp4a*, etc.) ([Figure 5C](#F5){ref-type="fig"}). Intriguingly, a group of genes involved in axon guidance (e.g., *Plxnd1*, *Plxnb2*, *Plxnc1*, etc.) are also repressed by MTA2 in pre-B cells ([Figure 5C](#F5){ref-type="fig"}). A comparison of our RNA-seq data with previously reported gene profiling data revealed that genes normally silenced during BM B cell differentiation from Hardy Fr C^′^ (cycling pre-B) to Fr D (resting pre-B) stages ([@R8]) are enriched in upregulated genes in *Vav-Cre Mta2*^fl/fl^ small pre-B cells ([Figure S5A](#SD1){ref-type="supplementary-material"}), indicating an important role of MTA2/NuRD at this development stage. Other MTA2-regulated genes that showed substantial upregulation (\>3.5-fold) include the following: *Crhbp*, *Atp11a*, *Trim63*, *Ikzf2* (*Helios*), *Gprasp2*, *Rcn3*, *H1f0*, etc. Our RNA-seq data also confirmed increased expression of *Igll1* and *VpreB1* genes in small pre-B cells. Among MTA2-repressed genes in small pre-B cells, about 70% have MTA2 binding sites at loci of their human orthologs in 697 cells ([Figure S5B](#SD1){ref-type="supplementary-material"}), suggesting that these are potential direct MTA2 target genes in mouse pre-B cells. It is noteworthy that only 96 genes (21% of upregulated genes in *Mta2*-deficient pro-B cells, 22% of upregulated genes in *Mta2*-deficient small pre-B cells) are repressed by MTA2 in both pro-B cells and in pre-B cells ([Figures 5C](#F5){ref-type="fig"} and [S5C](#SD1){ref-type="supplementary-material"}), suggesting that MTA2/NuRD regulates distinct transcriptional programs at different B cell developmental stages. The expression levels of a selected group of genes identified in *Mta2-*deficient pre-B cells by RNA-seq analyses have also been validated by RT-qPCR assays using cohorts of mice different from those used for RNA-seq analyses ([Figure S5D](#SD1){ref-type="supplementary-material"}).

Derepression of Pre-BCR Genes and a Pre-B to Immature B Transition Defect in Mice Lacking Both *Mta2* and *Oca-B* Genes {#S7}
-----------------------------------------------------------------------------------------------------------------------

In addition to the fact that AIOLOS is a key transcription factor in repression of *lgll1* and *VpreB1* genes at the pre-B cell stage ([@R44]), we previously found that the B cell-selective transcription coactivator OCA-B also represses *Igll1* and *VpreB1* genes at the pre-B stage through an interaction with SYK kinase in the cytoplasm ([@R40]). Interestingly, the joint loss of AIOLOS and OCA-B caused a greater derepression of *lgll1* and *VpreB1* genes in pre-B cells than was observed in either of the single-KO mice, and also caused a more severe defect in the pre-B to immature B cell transition ([@R14]). To determine whether MTA2 also synergizes with OCA-B in a similar fashion, we generated *Vav-Cre Mta2* ^fl/fl^*;Oca-B*^−/−^ mice (*DKO*) and examined BM B cell development in these mice. As shown in [Figures 6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}, the total number of BM cells in *DKO* mice decreased to one-third of the number in control mice, and both immature B and mature (recirculating) B cells showed 50% reductions. However, the population sizes of immature B and mature B cells showed 10-fold or more reductions, which are much more severe than those observed in either *Vav-Cre Mta2*^fl/fl^ ([Figures 2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}) or *Oca-B*^−/−^ ([Figures 6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}) mice. Like *Vav-Cre Mta2*^fl/fl^ mice, the *DKO* mice also showed an increased large pre-B to small pre-B cell ratio and abnormal Ig light chain κ rearrangements ([Figures 6C](#F6){ref-type="fig"} and [6D](#F6){ref-type="fig"}).

We further examined the expression of *Igll1* and *VpreB1* genes in *Oca-B*^−/−^ and *DKO* pre-B cells. While *Oca-B*^−/−^ pre-B cells exhibited an approximate 3-fold increase of *Igll1* and *VpreB1* expression levels, the *DKO* pre-B cells show a 10- to 20-fold increase of *Igll1* and *VpreB1* expression ([Figure 6E](#F6){ref-type="fig"}), demonstrating a synergy between OCA-B and MTA2/NuRD in *Igll1* and *VpreB1* repression at the pre-B stage. To further explore the possibility that OCA-B may directly regulate transcription of *Igll1* and *VpreB1*, ChIP and *OCA-B* knockdown experiments were carried out in 697 cells. As shown in [Figures 6F](#F6){ref-type="fig"} and [S6](#SD1){ref-type="supplementary-material"}, the results not only demonstrate binding of both OCA-B and its interacting transcription factor OCT2 to *IGLL1* and *VPREB1* promoters but also confirm the *OCA-B*-mediated repression of *IGLL1* and *VPREB1* in pre-B cells---thus indicating a potential repression function of OCA-B.

The Role of MTA2 in the Differentiation and Function of Splenic B Cells {#S8}
-----------------------------------------------------------------------

Unlike what is observed in *Mta2* Δ/Δ mice ([Figure 1C](#F1){ref-type="fig"}), but similar to what is observed in *Cd19-Cre Mta2*^fl/fl^ or *Mb1-Cre* Mta2^fl/fl^ mice ([Figure S2](#SD1){ref-type="supplementary-material"}), *Vav-Cre Mta2*^fl/fl^ mice show an increased MZB population that is about 2-fold the size of that in control mice ([Figures 7A](#F7){ref-type="fig"} and [7E](#F7){ref-type="fig"}). The size of the FOB population is largely unaffected in these mice ([Figures 7A](#F7){ref-type="fig"} and [7E](#F7){ref-type="fig"}). To assess the effect of MTA2 inactivation on the B cell response to immunization, we immunized *Vav-Cre Mta2*^fl/fl^ and control mice with SRBCs (sheep red blood cells) for 9.5 days and then examined the differentiation of germinal center B (GC B) cells (B220^+^CD95^+^CD38^−^CD4^−^) in these mice. As shown in [Figures 7B](#F7){ref-type="fig"} and [7C](#F7){ref-type="fig"}, *Mta2* inactivation leads to the production of more GC B cells during the immune response. *In vitro Ig* class switch assays also show abnormal class switching to *IgG1* and to *IgA* in the absence of MTA2 ([Figure S7](#SD1){ref-type="supplementary-material"}), suggesting an important role of MTA2/NuRD during an immune response.

Beyond a strong functional synergy between MTA2 and OCAB in the pre-B to immature B transition, as shown in [Figure 6](#F6){ref-type="fig"}, the dramatic loss of recirculating B cells in DKO mice also suggests a severe defect in splenic B cell development in these mice. A previous study has demonstrated a greater loss of splenic B cells in *Aiolos*^−/−^*, Oca-B*^−/−^ mice in comparison to either *Aiolos*^−/−^ or *Oca-B*^−/−^ mice ([@R42]). Similarly, while neither *Vav-Cre Mta2*^fl/fl^ nor *Oca-B*^−/−^ mice showed substantial loss of FOB cells, and only *Oca-B*^−/−^ but not *Vav-Cre Mta2*^fl/fl^ mice showed a decrease in the MZB cell population ([Figures 7D](#F7){ref-type="fig"} and [7E](#F7){ref-type="fig"}), the *DKO* mice exhibited dramatic decreases in both FOB and MZB populations---thus demonstrating an MTA2 and/or OCA-B requirement for the development of splenic B cell compartments ([Figures 7D](#F7){ref-type="fig"} and [7E](#F7){ref-type="fig"}). These data further support our hypothesis that AIOLOS functions in peripheral B cells through its interaction with MTA2/NuRD.

DISCUSSION {#S9}
==========

Despite intensive studies of key transcription factors involved in B cell lineage specification and development, less is clear about the roles of transcription cofactors such as chromatin regulators during this process. Here, through a combination of genetic, biochemical, and genomic approaches, we directly assessed the contributions of NuRD corepressor complexes to BM and splenic B cell development.

Our data demonstrate that MTA2/NuRD plays an important role at multiple stages during B cell development in BM and spleen. Initially, we found decreased BM B cell subsets (pro-B, pre-B, and immature B populations) and MZB cells in *Mta2* Δ/Δ mice. Surprisingly, neither *Cd19-*Cre *Mta2*^fl/fl^ nor *Mb1-*Cre *Mta2*^fl/fl^ mice recapitulated the BM defects observed in *Mta2* Δ/Δ mice. The incomplete deletion efficiencies observed in *Cd19-*Cre *Mta2*^fl/fl^ and *Mb1-*Cre *Mta2*^fl/fl^ pro-B cells are likely an important factor for causing this phenomenon. In contrast, *Vav-*Cre *Mta2*^fl/fl^ mice exhibit optimal deletion efficiency in pro-B, pre-B, and immature B cells and recapitulate the BM B cell development defects of *Mta2* Δ/Δ mice. We also show that *Mta2* inactivation causes abnormal rearrangements of Ig heavy chain genes in pro-B cells. In relation to Ig light chain rearrangements in pre-B cells, our data suggest a greater effect of *Mta2* inactivation on more distal events relative to proximal events, likely a result of premature termination of recombination processes. Loss of MTA2 also leads to an increased large pre-B to small pre-B ratio and a decrease in the small pre-B population, suggesting a cell cycle defect at the pre-B stage and a likely effect on the pre-B to immature B cell transition. In the spleen, where *Mta2* Δ/Δ mice show an approximate 5-fold reduction of MZB cells, the *Cd19-*Cre *Mta2*^fl/fl^, *Mb1-*Cre *Mta2*^fl/fl^, and *Vav-*Cre *Mta2*^fl/fl^ mice show, instead, an approximately 2-fold increase in MZB cells. These results suggest a potential B cell-extrinsic role for MTA2 (e.g., in stromal cells) in regulating MZB population size in *Mta2* Δ/Δ mice.

At the molecular level, gene profiling analyses have identified genes suppressed by MTA2 in pro-B cells and small pre-B cells (non-dividing pre-B cells). GO analyses indicate that MTA2/NuRD regulates distinct transcriptional programs in pro-B and pre-B cells. In pro-B cells, the major pathways suppressed by MTA2/NuRD include neutrophil degranulation and activation, cell junction and ECM, inflammation response, macromolecule metabolism, and endocytosis ([Figure 5C](#F5){ref-type="fig"}). In pre-B cells, the major pathways repressed by MTA2/NuRD include TCR signaling and T cell differentiation, regulation of apoptosis, and axon guidance ([Figure 5C](#F5){ref-type="fig"}). It thus appears that MTA2/NuRD is involved in the repression of non-B lineage genes at both pro-B and pre-B stages. Furthermore, a gene set enrichment analysis (GSEA) indicates that genes normally silenced during Hardy Fr C^′^ (cycling pre-B) to Hardy Fr D (resting pre-B) differentiation are enriched in upregulated genes in *Mta2*-deficient small pre-B cells.

It is worth noting that, although other MTA family member genes, namely *Mta3* and *Mta1*, are also expressed in different B subsets cells, our data demonstrate non-redundant functions of MTA2 during B cell development. Further analyses are required to elucidate the unique function of MTA1 and MTA3 and redundant function between MTA family members during B cell development.

The B cell phenotypes described above and other defects of immune system caused by loss of MTA2 function are strikingly similar to those associated with loss of AIOLOS function ([Table S5](#SD1){ref-type="supplementary-material"}; [@R14]; [@R27]; [@R42]; [@R46]). Consistent with previous observations of an IKAROS/AIOLOS/NuRD association in T cells ([@R16]; [@R52]), we have shown a physical interaction between AIOLOS/IKAROS and MTA2/NuRD in B cells. This observation opened a window into the functional interplay between AIOLOS/IKAROS and MTA2/NuRD complexes. Specifically, it was already noted that *Igll1* and *VpreB1*, two genes central to the pre-B cell differentiation, are derepressed in *Aiolos*^−/−^ pre-B cells ([@R44]). Conversely, overexpression of IKAROS in B3 mouse pre-B cells recruits MI-2β and MBD3 to its binding sites and causes rapid RNA polymerase II eviction, reduced promoter accessibility, and repression of Ikaros-bound genes that include *Igll1* and *VpreB1* in a MI-2β-dependent manner ([@R8]; [@R25]). In this study, our data from RT-qPCR, ChIP-qPCR, and ChIP-seq analyses all strongly support a model in which AIOLOS/IKAROS represses pre-BCR gene expression through an interaction with MTA2/NuRD.

Beyond pre-BCR gene loci, genome-wide mapping of AIOLOS, IKAROS, HDAC2, and MTA2 binding sites in human 697 cells showed a highly significant overlap between AIOLOS/IKAROS targets and NuRD targets ([Figures 4C](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}). Motif analyses showed that EBF1, RUNX1/2, and ETS family binding sites are among the top motifs enriched in DNA sequences bound by AIOLOS, IKAROS, HDAC2, and MTA2. Integration of ChIP-seq data with gene profiling data showed that the human orthologs of about 70% of the upregulated genes in *Vav-Cre Mta2*^fl/fl^ pre-B cells are direct MTA2 targets in human pre-B cells. These data support the hypothesis that transcriptional repression through NuRD and transcription repressors (such as AIOLOS/IKAROS) might be achieved, at least in part, by competition with transcription activators (such as EBF1) and associated coactivators (such as p300/CBP) at promoters or enhancer elements.

At the periphery, while both *Mta2* Δ/Δ and *Aiolos*-null mice show loss of MZB cells, the *Mta2* B cell-specific null mice (*Cd19-Cre-*, *Mb1-Cre*, and *Vav-Cre Mta2*^fl/fl^) show an increase of MZB cells, implying a possible stromal cell-related MTA2 function that affects the MZB population size. It will be interesting to determine whether the B cell-specific inactivation of *Aiolos* leads to a similar phenotype. Consistent with the B cell activation phenotype in *Aiolos*-null mice, we observed increased GC B cell production in response to SRBC stimulation in *Vav-Cre Mta2*^fl/fl^ mice. It is worth noting that B cell-specific *Ikaros* KO mice also show dramatic losses of pre-B, immature B, and recirculating B in bone marrow, and both MZB and FOB cells in spleen, but increased splenic B1-B cells ([@R29]; [@R37])---demonstrating non-redundant functions of different IKAROS family members during B cell development.

OCA-B is a transcription coactivator that plays an essential role in GC formation and transcription of secondary Ig genes, and that is also involved in B cell development in the bone marrow ([@R28]; [@R40]). Our previous study had shown that OCA-B represses pre-BCR genes *Igll1* and *VpreB1* in pre-B cells, likely through its interaction with SYK kinase in the cytoplasm ([@R40]). However, the current ChIP data demonstrate a direct binding of OCA-B and its interacting transcription factor OCT2 at *IGLL1* and *VPREB1* promoters in 697 cells. Moreover, *OCA-B* knockdown in 697 cells reproduces the derepression of *Igll1* and *VpreB1* genes. Notably, these results indicate an important and previously unrecognized repressive function of OCA-B at these gene loci. Similar to what was observed in *Aiolos*^−/−^*; Oca-B*^−/−^ mice ([@R14]), we observed a substantial increase in *Igll1* and *VpreB1* expression in *Vav-Cre Mta2*^fl/fl^*; Oca-B*^−/−^ pre-B cells, along with a severe developmental block in the pre-B to immature B transition and a significant loss of MZB and FOB cells in the spleen. These data further support our model in which AIOLOS depends on MTA2/NuRD to execute its function both in BM pre-B cells and in peripheral B cells. This synergy is significant since several previous studies exploring genetic interactions of OCA-B with OCT2, NFkB, and BTK did not show severe BM B cell developmental defects in respective double-mutant mice ([@R17]; [@R35], [@R36]). The increased MZB cells in *Vav-Cre Mta2*^*fl/fl*^ mice and the dramatic losses of MZB cells in both *Oca-B*^−/−^ and DKO mice suggest that OCA-B functions downstream of MTA2/NuRD in regulating MZB cell differentiation.

In summary, our analysis of *Mta2*-deficient mice demonstrates an important role of the MTA2/NuRD complex in B cell development. The phenotypic similarity, physical interaction, and overlapping genome-wide binding sites between MTA2 and AIOLOS/IKAROS present a striking example in which inactivation of a transcription cofactor (MTA2) recapitulates the defects caused by inactivation of a transcription factor (AIOLOS) *in vivo*, strongly suggesting a mutual functional dependence between MTA2/NuRD and AIOLOS/IKAROS during B cell development. Our data have also demonstrated a strong genetic interaction between MTA2/NuRD and OCA-B in regulating *Igll1* and *VpreB1* expression and the pre-B to immature B cell transition. The *Vav-Cre Mta2*^fl/fl^*; Oca-B*^−/−^ model could serve as a platform for future elucidation of key pathways controlling the pre-B to immature B cell checkpoint and peripheral B cell development.

STAR★METHODS {#S10}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S11}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Robert G. Roeder (<roeder@rockefeller.edu>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S12}
--------------------------------------

### Mice {#S13}

Mice were maintained in environmental control facilities at the Rockefeller University and the University of North Carolina at Chapel Hill. Mice of both sexes were 8 to 12 weeks old unless otherwise indicated. The mouse maintenance and experiments were performed following the Institutional Animal Care and Use Committee (IACUC) approved protocols of the Rockefeller University and University of North Carolina at Chapel Hill. Mice carrying *Mta2* conditional alleles (*Mta2*^fl/fl^) were generated as described before ([@R27]). The *Cd19-Cre* mice, *Mb1-Cre* mice, *Mx1-Cre* transgenic mice, *Vav1-Cre* mice and *Oca-B* knockout (KO) mice were described previously ([@R12]; [@R15]; [@R21]; [@R31]; [@R32]). The *Mta2* KO mice (Δ/Δ) were derived by crossing *EIIa-Cre* transgenic mice with *Mta2*^fl/fl^ mice ([@R27]). *Mta2* Δ/Δ and littermate or age-matched control mice were of mixed B6/129 genetic background. The conditional KO mice had been backcrossed with C57/BL6 mice for at least six generations. For induction of *Mx1-Cre* transgene expression, *Mx1-Cre Mta2*^flfl^ and littermate *Mta2*^flfl^ mice received two intraperitoneal injections of poly (I:C) (250 mg) at day 28 and day 30 of age. Mouse genomic DNA was isolated using DNeasy Blood and Tissue Kit (QIAGEN) for genotyping. The primers for genotyping *Mta2* alleles and *Oca-B* alleles can be found in [Table S6](#SD1){ref-type="supplementary-material"}. The primers for genotyping other transgenic mouse strains described above can be found at the corresponding websites of The Jackson Laboratory (<https://www.jax.org/>).

### Cell Line {#S14}

697 cells are human pre-B leukemia cells that carry the E2A-PBX1 fusion gene ([@R13]) and were cultured with RPMI 1640, 10% fetal bovine serum (FBS). Namalwa cells are human Burkitt's lymphoma cells and were cultured with RPMI 1640, 10% FBS.

METHOD DETAILS {#S15}
--------------

### Flow Cytometry {#S16}

*Mta2* mutant and *Oca-B* mutant mice, and littermate control or age-, sex-matched control mice were used for analysis. Single cell suspensions of bone marrow cells and spleen cells were stained with FITC-, PE-, PerCP/Cy5.5-, PE/Cy7-, Brilliant Violet 605-, and APC-conjugated monoclonal antibodies (described in [Key Resources Table](#T1){ref-type="table"}) and DAPI. Stained cells were analyzed with either BD LSR II or BD FACSCalibur (BD Biosciences). The cell staining and gating schemes were indicated in the figures, figure legends and results. The specific B cell populations were sorted with BD FACSAria (BD Biosciences). The flow cytometry data were analyzed using BD FACSDiva and FlowJo softwares. For FACS analyses of bone marrow B cell subpopulations, two femurs from each mouse were used for immunofluorescence staining and cell sorting.

### Immunoprecipitation (IP) {#S17}

Dynabeads™ Protein G beads (Invitrogen) were first washed twice with PBS containing 0.5% BSA and 0.05% Triton X-100 then incubated with specific antibodies (about 2 mg antibody for each IP assay) in the same buffer for 2 to 3 h or overnight at 4°C. The conjugated antibodies then were incubated with nuclear extracts (NE) derived from 697 cells or Namalwa cells overnight at 4°C.About 200 mg of NE was used for each IP assay. After washing with buffer BC200 \[20 mM Tris (pH 7.9), 0.2 mM EDTA, 1 mM DTT, 0.2 mM PMSF, 20% glycerol, and 200 mM of KCl\] for three times, the immunoprecipitates were subject to immunoblot.

### RNA isolation and reverse transcription (RT) {#S18}

Total RNA was isolated from sorted primary B cells or cultured 697 cells using Arcturus™ PicoPure RNA isolation Kit (Applied Bio-systems). For each sample, 40 to 100 μg RNA was used for reverse transcription using qScript cDNA SuperMix (Quanta Biosciences) according to Manufacturer's instruction.

### Quantitative PCR {#S19}

Quantitative PCR (qPCR) assays were performed in triplicate using QuaniTect SYBR Green PCR mix (QIAGEN) on a 7300 Real Time PCR System (Applied Biosystems). The numbers of biological samples and independent experiments used for qPCR analyses are indicated in the figure legends and text. mRNA levels were normalized to the expression level of *Hprt* (*HPRT*) or *Gapdh* (*GAPDH*) gene in mouse and human cells. For deletion efficiency and immunoglobulin gene rearrangement analyses, genomic DNA amounts were normalized to promoter regions of *Cd79b* or *Cdk6* genes. Primer sequences for RT-qPCR and qPCR are listed in [Table S6](#SD1){ref-type="supplementary-material"}.

### RNA-seq and gene ontology {#S20}

For pro-B cell gene profiling, B220^+^IgM^−^CD43^+^ pro-B cells from 2 pairs of 10-week-old *Vav-Cre Mta2*^*fl/fl*^ and littermate control mice were sorted for RNA isolation. For pre-B cell gene profiling, B220^+^IgM^−^CD43^−^ small pre-B cells from 3 pairs of 10-week-old *Vav-Cre Mta2*^*fl/fl*^ and littermate control mice were sorted for RNA isolation. The RNA library preparation was done with TruSeq Stranded mRNA Prepration Kit (Illumina). The sequencing was done by the Genomics Core Facility at The Rockefeller University using an Illumina HiSeq 2500 Sequencer. Sequencing data were aligned to mm10 reference genome on Galaxy (<https://usegalaxy.org/>) with default parameters using TopHat software ([@R18]). The aligned sequences were assembled using Cufflinks and then analyzed using edgeR package in R script ([@R33]; [@R45]). The cut-off line for differential gene expression levels was 1.5 fold with p values smaller than 0.05. Enrichr (<http://amp.pharm.mssm.edu/Enrichr/>) was used for gene ontology analysis and GSEA was used for gene set enrichment analysis ([@R22]; [@R41]).

### Genomic rearrangement of the Immunoglobulin heavy chain and light chain loci {#S21}

B220^+^IgM^−^CD43^+^ pro-B and B220^+^IgM^−^CD43^−^ small pre-B cells from 4 pairs of 8 to 12-week-old *Vav-Cre Mta2*^*fl/fl*^ and littermate control mice were sorted, and the genomic DNA was isolated using DNeasy Blood and Tissue Kit (QIAGEN). The *V*~*H*~*(D)J*~*H*~ recombination efficiencies in pro-B cells were measured by qPCR using primers indicated in [Figure 2E](#F2){ref-type="fig"} and described in [Table S6](#SD1){ref-type="supplementary-material"}. The *V*~*K*~*J*~*K*~ recombination efficiencies in pre-B cells were measured by qPCR using primers indicated in [Figure 2G](#F2){ref-type="fig"} and described in [Table S6](#SD1){ref-type="supplementary-material"}. A universal *V*~*k*~ primer was used in combination with a *J*~*k*~*1*, *J*~*k*~*2*, *J*~*k*~*4* or *J*~*k*~*5* primer. Promoter regions of *Cd79b* or *Cdk6* genes were used to normalize genomic DNA amounts of different samples. The number of samples used in the assays can be found in the corresponding Figure Legends.

### Chromatin immunoprecipitation (ChIP) and ChIP-sequencing {#S22}

The antibodies used for ChIP are described in [Key Resources Table](#T1){ref-type="table"}. Normal rabbit IgG (sc-2027, Santa Cruz Biotechnology Inc.) was used as an immunoprecipitation control. In ChIP experiments, cells were incubated sequentially, at room temperature (RT), for 30 min in 2mM disuccinimidyl glutarate (DSG), for 10 min after formaldehyde addition to a final concentration of 1%, and for 5 min after addition of glycine to a final concentration of 125mM. Fixed cells were washed twice with cold PBS and resuspended in RIPA 0.3 buffer(0.1% SDS, 1% Triton X-100, 10mM Tris-HCl(pH7.4), 1mM EDTA (pH8.0), 0.1% Sodium Deoxycholate, and 0.3M NaCl). The antibodies and IgG were first incubated with Dynabeads Protein G (Invitrogen) at 4°C overnight, then washed and then incubated with sonicated cell lysate (1--2ug antibody for a ChIP-qPCR, 6--10ug antibody for ChIP-seq) at 4° overnight. For reverse crosslinking, the beads were first washed 4--8 times with high salt buffer (20mM Tris pH8, 2mM EDTA, 0.1%SDS, 1%TX100, 500mM NaCl), then washed with TE buffer (pH8.0) and then washed with elution buffer (1% SDS in TE buffer) for 15 min at RT. Eluates were then incubated at 65°C for 4 h after addition of NaCl and RNase to final concentrations of 200mM and 4ug/ml and then at 55°C for 1 h after addition of proteinase K to100ug/ml. Finally, the immunoprecipitated DNA samples were purified by QIAquick PCR Purification Kit (QIAGEN) for further analysis. About 2--5 ng of DNA precipitated by ChIP was used as the starting material for the generation of single-end sequencing libraries as described ([@R51]). Cluster generation and sequencing was performed by the Genomics Resource Center at The Rockefeller University with a HiSeq 2500 system with a read length of 50 nucleotides according to the manufacturer's guidelines (Illumina).

### Data analysis for ChIP-seq {#S23}

The softwares used for ChIP-seq data analyses are listed in [Key Resources Table](#T1){ref-type="table"}. In brief, sequencing data were aligned using Bowtie2 ([@R23]) to hg19 version of the reference genome on Galaxy (<https://usegalaxy.org/>) with default parameters. Duplicate mapped reads were removed using Samtools with the rmdup option. Bedgraph files were generated by Homer using makeUCSCfile program with default parameters ([@R24]). ChIP-seq tracks generated by converting bedgraph files to tdf formats were displayed by IGV software ([@R34]). Peak files were generated by Homer using findPeaks program with default parameters ([@R11]). The threshold for statistical significance of peaks was set at 10^−10^. Annotation of filtered peaks was done by Homer with annotatePeaks program with default parameters except -style factor. ChIP-seq signals at TSSs were plotted as averaged profiles or heatmaps by ngsplot with parameter -SC global -GO max. ChIP-seq signals at enhancers were plotted as averaged profiles by ngsplot with parameter -L 10000 -F Gm12878 -SC global -GO max ([@R39]). Motif analyses were performed by Homer using findMotifsGenome program with default parameters.

### shRNA knockdown {#S24}

For knockdown of the *OCA-B* gene, 1×10^7^ 697 cells were infected with lentivirus carrying OCA-B shRNA sequences or scramble RNA sequence plus 8 mg/ml polybrene in RPMI 1640 medium with 10% FBS. After 12 h, the infected cells were changed to fresh medium with 10% FBS and cultured for 2 days. The cells were then treated with 1 mg/ml puromycin and cultured for another 2 days. Total RNAs were isolated for measuring expression levels of OCA-B by RT-qPCR.

### Immunization and immunoglobulin (Ig) class switch {#S25}

Sheep red blood cells (SRBC) were washed with PBS and 1:10 diluted in PBS. 500 mL diluted SRBC were intraperitoneal injected to each mouse. Splenic cells were isolated on day 9 or day 10 after immunization for FACS analysis of germinal center B cells. For *Ig* class switch assay, naive splenic B cells were enriched by negative selection using anti-CD43 conjugated magnetic beads (Miltenyi Biotec). Isolated cells, at a concentration of 300 to 500K cell per ml, were incubated in RPMI 1640 medium with 10% FCS. *Ig* class switching were induced by 5ng/ml IL-4 (Sigma) + 25ug/ml LPS (Sigma) (for *IgG1*), 25ug/ml LPS (for *IgG3*), and 5ng/ml IL-4 + 0.2mg/ml anti-CD40 antibody (BioLegend) + 0.1ng/ml TGF-β (BioLegend) (for *IgA*) respectively. After incubation for three days, the cells were analyzed by flow cytometry for specific Ig surface markers.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S26}
---------------------------------------

All data were analyzed using Excel or GraphPad Prism softwares. t tests were used for calculation of statistical significance when comparing data from two groups. Differences were considered significant when p values were \< 0.05. p values are depicted in figures using one to three asterisks (\*p \< 0.05, \*\*p \< 0.01, and \*\*\*p \< 0.005). Data are presented as mean + SD with n indicating the number of animals or independent experiments if not stated otherwise in the figure legends or in the text.

DATA AND CODE AVAILABILITY {#S27}
--------------------------

The RNA-seq and ChIP-seq data have been deposited in NCBI Gene Expression Omnibus. The accession number for the RNA-seq data reported in this paper is GSE107885, and the accession number for the ChIP-seq data reported in this paper is GSE107886.
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![BM and Peripheral B Cell Developmental Defects in the Conventional *Mta2* Null Mice\
(A) Flow cytometry data of BM cells from a 2-month-old *Mta2* Δ/Δ and a littermate wild type control mouse stained for immature B (B220^lo^IgM^+^), mature B (B220^hi^IgM^+^), pro-B (B220^+^IgM^−^CD43^+^), and pre-B (B220^+^IgM^−^CD43^−^) cell populations. Numbers indicate percentages of specific cell subsets in parental populations.\
(B) Cell numbers of different BM B cell sub-populations (from two femurs) in 1.5- to 2.5-month-old control and *Mta2* Δ/Δ mice (n = 11 for control and n = 5 for mutant mice; t test; \*p \< 0.05, \*\*p \<0.01, \*\*\*p \< 0.001).\
(C) FACS analysis of total splenic B (IgM^+^B220^+^), MZB (IgM^+^B220^+^CD21^hi^CD23^lo^), and FOB (IgM^+^B220^+^CD21^−^CD23^hi^) cells from a 4-month-old *Mta2* Δ/Δ mouse and a wild-type (WT) litter-mate control mouse.\
(D) Numbers of total splenic B, MZB, and FOB cells from 2- to 4-month-old wild-type and *Mta2* Δ/Δ mice are plotted (n = 10 for each genotype; t test; \*\*\*p \< 0.001).](nihms-1534204-f0002){#F1}

![*Vav-Cre Mta2*^*fl*/fl^ Mice Recapitulate the BM B cell Developmental Defects of Mta2Δ/Δ Mice\
(A) BM cells from mice with indicated *Mta2* status stained for immature B (B220^lo^IgM^+^), mature B (B220^hi^IgM^+^), pro-B (B220^+^IgM^−^CD43^+^), and pre-B (B220^+^IgM^−^CD43^−^) cell populations. Numbers indicate percentages of specific cell subsets in parental populations.\
(B) Cell numbers of different BM B cell subsets (from two femurs) in 2- to 3-month-old *Vav-Cre Mta2*^fl/fl^ and littermate or age-matched control mice (n ≥ 16 for *Vav-Cre Mta2*^fl/fl^ and control mice; t test; \*\*p \< 0.01, \*\*\*p \< 0.001).\
(C) qPCR results indicating efficiencies of Vav-Cre-mediated deletion of *Mta2* allele in indicated cell populations (n = 4 for each cell subsets; t test; \*\*\*p \< 0.001).\
(D) Representative FACS data showing percentages of Hardy Fr. A to C within the pro-B population in *Vav-Cre Mta2*^fl/fl^ and control mice. The average numbers of each fractions are plotted (n = 9 for each genotype; t test; \*\*p \< 0.01).\
(E) qPCR results indicating relative abundances of different immunoglobulin heavy chain gene rearrangements in pro-B cells isolated from mice with indicated genotypes (n = 4 for each genotype).\
(F) Representative FACS data showing percentages of large (L) and small (S) pre-B (B220^+^IgM^−^CD43^−^) cells in *Vav-Cre Mta2*^fl/fl^ and control mice. The average numbers of each type of pre-B cells from mice with indicated genotypes are plotted (n ≥ 13 for *Vav-Cre Mta2*^fl/fl^ and littermate control mice; t test; \*\*\*p \< 0.001).\
(G) qPCR results indicating relative abundances of different VJ rearrangements in small pre-B cells isolated from mice with indicated genotypes (n = 4 for each genotype; t test; \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001).](nihms-1534204-f0003){#F2}

![MTA2/NuRD Interacts with AIOLOS and Represses *Igll1* and VpreB Genes in Pre-B Cells\
(A) Immunoprecipitation (IP)-Western blot results using 697 human pre-B leukemia cell nuclear extract (NE). Antibodies used for IPs and immunoblots are marked (AIO: AIOLOS, IKA: IKAROS).\
(B) RT-qPCR results showing expression levels of *Igll1* and *VpreB1* genes in pre-B cells isolated from *Vav-Cre Mta2*^fl/fl^, *Mx1-Cre Mta2*^fl/fl^ and their litter-mate control mice (n = 4 for *Vav-Cre Mta2*^fl/fl^ and control, n = 3 for *Mx1-Cre Mta2*^fl/fl^ and control; t test; \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001).\
(C) ChIP-qPCR data using human 697 cells showing enrichment of AIOLOS, MI-2β, MTA2 (left panel), and IKAROS (right panel) at the *IGLL1* and *VPREB1* promoter regions. The *CNAP1* gene locus was used as a negative region control. Data were collected from 3 or more independent ChIP assays.\
(D) ChIP-qPCR data showing enrichment of H3K27Ac and H3K4Me3 marks (normalized to H3) at promoter regions of *Igll1* and *VpreB1* genes in primary small pre-B cells sorted from *Vav-Cre Mta2*^fl/fl^ (*VavKO*) and control mice (t test; \*p \< 0.05, \*\*p \< 0.01).](nihms-1534204-f0004){#F3}

![Genome-Wide Mapping of MTA2, HDAC2, AIOLOS, and IKAROS in Human Pre-B Cells\
(A) Distribution of MTA2, HDAC2, AIOLOS, and IKAROS binding sites at different genomic locations in 697 human pre-B cells. Numbers indicate the percentage of total sites at each location.\
(B) Meta-gene analysis of average enrichment of indicated factors around transcription start sites (TSSs) (left panel) and enhancers (right panel).\
(C) Venn diagrams showing significant overlaps between AIOLOS, MTA2, and HDAC2 target genes (left panel) and between IKAROS and AIOLOS target genes (right panel).\
(D) A heatmap generated by normalized read densities from individual ChIP-seq data (AIO, AIOLOS; IKA, IKAROS) centered at TSS and ranked by AIOLOS peak signals.\
(E) Consensus AIOLOS-, IKAROS, MTA2, and HDAC2 recognition sequences identified by *de novo*-motif identification in 697 cells. The more detailed summaries of DNA motifs recognized by these factors are listed in [Tables S1](#SD1){ref-type="supplementary-material"}--[S4](#SD1){ref-type="supplementary-material"}.\
(F) ChIP-seq snapshots of AIOLOS, IKAROS, HDAC2, and MTA2 binding at pre-BCR gene promoters in 697 cells. The scales of ChIP-seq signals are indicated.](nihms-1534204-f0005){#F4}

![Distinct MTA2-Dependent Transcriptional Programs in Mouse Pro-B and Pre-B Cells\
(A) Heatmaps based on RNA-seq data from *Vav-Cre Mta2*^fl/fl^ (*VavKO*) and control pro-B (left) and small pre-B (right) cells.\
(B) Numbers of genes that show increased or decreased expression in pro-B and small pre-B cells upon loss of *Mta2* (threshold 1.5-fold).\
(C) Gene ontology (GO) analyses of MTA2-regulated pathways and processes in pro-B and small pre-B cells (black, 1.5- to 3-fold change; blue, 3--5-fold; red, \>5-fold).](nihms-1534204-f0006){#F5}

![Joint Loss of MTA2 and OCA-B Causes Severe BM B Cell Developmental Defects\
(A) Staining and gating of the of bone marrow B cell compartments in control, *Vav-Cre Mta2*^fl/fl^, *Oca-B*^−/−^, and *DKO* mice. Frequencies of indicated sub-populations are marked.\
(B) Cell numbers of different B cell subsets (from two femurs) are plotted (n = 15 for control, n = 10 for *Oca-B*^−/−^, and n = 7 for DKO mice; t test; \*p \< 0.05, \*\*\*p \< 0.001).\
(C) Representative FACS data showing frequencies of large pre-B (L) and small pre-B (S) cells in mice with indicated genotypes.\
(D) Real-time PCR results indicating relative abundances of different Ig light chain VJ rearrangements in small pre-B cells isolated from mice with indicated genotypes (n = 4 for each genotype; t test, \*p \< 0.05).\
(E) RT-qPCR results showing increased *Igll1* and *VpreB1* expression levels in *Oca-B*^−/−^ and *DKO* pre-B cells (n ≥ 3 for each genotype; t test; \*p \< 0.05, \*\*p \< 0.01).\
(F) ChIP-seq snapshots of OCA-B and OCT2 binding at *IGLL1* and *VPREB1* promoter regions in 697 cells. The scales of ChIP-seq signals are indicated.](nihms-1534204-f0007){#F6}

![Abnormal Splenic B Cell Differentiation and B Cell Response in Mice Lacking MTA2 or Both MTA2 and OCA-B\
(A) Staining of total splenic B (B220^+^), marginal zone B (MZB) (B220^+^CD21^hi^CD23^lo^), and follicular B (FOB) (B220^+^CD21^−^CD23^hi^) cells in *Vav-Cre Mta2*^fl/fl^ and control mice. Frequencies of different cell populations in parental cells are indicated.\
(B) Staining of germinal center B (GCB) (B220^+^CD95^+^CD38^−^CD4^−^) cells in *Vav-Cre Mta2*^fl/fl^ and control mice immunized by sheep red blood cells (SRBCs).\
(C) Numbers of GCB cells and frequencies of GCB cells in splenic B cells are plotted (n = 8 for each genotype; t test; \*p = 0.02).\
(D) Staining of splenic B, MZB, and FOB cells in mice with indicated genotypes.\
(E) Cell numbers of different B cell subsets are plotted (n = 10 for control, n = 9 for *Vav-Cre Mta2*^fl/fl^, n = 5 for *Oca-B*^−/−^ and DKO mice; t test; \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001).](nihms-1534204-f0008){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                      SOURCE                       IDENTIFIER
  -------------------------------------------------------- ---------------------------- ---------------------------------------------------------
  Antibodies                                                                            
  PE/Cy7 anti-mouse/human CD45R/B220                       BioLegend                    Cat\# 103222; RRID: AB_313005
  PE anti-mouse IgM                                        BioLegend                    Cat\# 406508; RRID: AB_315058
  APC anti-mouse IgM                                       BioLegend                    Cat\# 406509; RRID: AB_315059
  FITC anti-mouse CD43                                     BioLegend                    Cat\# 143204; RRID: AB_10960745
  FITC anti-mouse CD21/CD35 (CR2/CR1)                      BioLegend                    Cat\# 123407; RRID: AB_940403
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###### Highlights

-   Loss of MTA2 causes bone marrow and splenic B cell developmental defects in mice

-   Loss of MTA2 causes derepression of *Igll1* and *VpreB1* genes in pre-B cells

-   MTA2 binding sites highly overlap AIOLOS/IKAROS binding sites in pre-B cells

-   MTA2 cooperates with OCA-B in regulating pre-B to immature B transition
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